Thu, Jul 24, 2014, 4:43 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Arena Pharmaceuticals, Inc. Message Board

  • rondiamond510 rondiamond510 Jan 15, 2013 2:46 PM Flag

    Huge Catalysts Jan 18th DEA Coming. post.

    Seeking Alpha
    1/15/13 By: RX Stocks
    Arena's (ARNA) obesity drug, Belviq, was approved on June 27, 2012 and should receive final scheduling by the DEA soon. The DEA recommended Schedule 4 and is collecting comments through January 18, 2013, then a final decision should be forthwith. European approval may also be imminent (see Seeking Alpha), which could be a game changer. Vivus' (VVUS) drug Qsymia did not get European approval, which will give Belviq exclusivity in the European obesity market. The European sales potential for Belviq and a relatively weak start for Qsymia sales has lead to a change in my previous opinion, published by Seeking Alpha, for Arena's growth potential.

 
ARNA
4.85-0.03(-0.51%)4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.